ID   AT5BIVA
AC   CVCL_7442
SY   AT5BiSv40; AT5BISV40; ATSV1; GM05849; GM5849; GM5849C; GM05849A; GM05849B
DR   CLO; CLO_0024705
DR   Coriell; GM05849
DR   Lonza; 258
DR   TOKU-E; 4105
DR   Wikidata; Q54750948
RX   CelloPub=CLPUB00447;
RX   PubMed=2821020;
RX   PubMed=2903889;
RX   PubMed=2987007;
RX   PubMed=3023120;
RX   PubMed=9357546;
RX   PubMed=9650596;
RX   PubMed=11172010;
RX   PubMed=12419185;
RX   PubMed=14555701;
RX   PubMed=18757420;
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu2427_Arg2428del (c.7278_7283delCCTTAG); ClinVar=VCV000003020; Zygosity=Heterozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC   Misspelling: GM5489; PubMed=2987007.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Cell type: Fibroblast of skin; CL=CL_0002620.
DI   NCIt; C2887; Ataxia telangiectasia syndrome
DI   ORDO; Orphanet_100; Ataxia telangiectasia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_7441 ! AT5BI
SX   Male
AG   18Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 25
//
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992).
//
RX   PubMed=2821020; DOI=10.1242/jcs.1984.Supplement_6.8;
RA   Green M.H.L., Lowe J.E., Arlett C.F., Harcourt S.A., Burke J.F.,
RA   James M.R., Lehmann A.R., Povey S.;
RT   "A gamma-ray-resistant derivative of an ataxia telangiectasia cell
RT   line obtained following DNA-mediated gene transfer.";
RL   J. Cell Sci. Suppl. 6:127-137(1987).
//
RX   PubMed=2903889; DOI=10.1080/09553008814552321;
RA   Arlett C.F., Green M.H.L., Priestley A., Harcourt S.A., Mayne L.V.;
RT   "Comparative human cellular radiosensitivity: I. The effect of SV40
RT   transformation and immortalisation on the gamma-irradiation survival
RT   of skin derived fibroblasts from normal individuals and from
RT   ataxia-telangiectasia patients and heterozygotes.";
RL   Int. J. Radiat. Biol. 54:911-928(1988).
//
RX   PubMed=2987007; DOI=10.1016/0014-4827(85)90437-9;
RA   Murnane J.P., Fuller L.F., Painter R.B.;
RT   "Establishment and characterization of a permanent pSV ori-transformed
RT   ataxia-telangiectasia cell line.";
RL   Exp. Cell Res. 158:119-126(1985).
//
RX   PubMed=3023120; DOI=10.1016/0014-4827(87)90418-6;
RA   Hahn P., Kapp L.N., Painter R.B.;
RT   "Establishment and characterization of two human cell lines with
RT   amplified dihydrofolate reductase genes.";
RL   Exp. Cell Res. 168:89-94(1987).
//
RX   PubMed=9357546; DOI=10.1016/s0027-5107(97)00119-x;
RA   Sprung C.N., Bryan T.M., Reddel R.R., Murnane J.P.;
RT   "Normal telomere maintenance in immortal ataxia telangiectasia cell
RT   lines.";
RL   Mutat. Res. 379:177-184(1997).
//
RX   PubMed=9650596; DOI=10.2307/3579639;
RA   Enns L., Barley R.D.C., Paterson M.C., Mirzayans R.;
RT   "Radiosensitivity in ataxia telangiectasia fibroblasts is not
RT   associated with deregulated apoptosis.";
RL   Radiat. Res. 150:11-16(1998).
//
RX   PubMed=11172010; DOI=10.1073/pnas.041416598;
RA   Peretz S., Jensen R., Baserga R., Glazer P.M.;
RT   "ATM-dependent expression of the insulin-like growth factor-I receptor
RT   in a pathway regulating radiation response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:1676-1681(2001).
//
RX   PubMed=12419185; DOI=10.1016/s0960-9822(02)01259-9;
RA   Kobayashi J., Tauchi H., Sakamoto S., Nakamura A., Morishima K.-i.,
RA   Matsuura S., Kobayashi T., Tamai K., Tanimoto K., Komatsu K.;
RT   "NBS1 localizes to gamma-H2AX foci through interaction with the
RT   FHA/BRCT domain.";
RL   Curr. Biol. 12:1846-1851(2002).
//
RX   PubMed=14555701;
RA   Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D.,
RA   Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.;
RT   "Telomerase inhibition and cell growth arrest by G-quadruplex
RT   interactive agent in multiple myeloma.";
RL   Mol. Cancer Ther. 2:825-833(2003).
//
RX   PubMed=18757420; DOI=10.1158/0008-5472.CAN-08-0545;
RA   Burdak-Rothkamm S., Rothkamm K., Prise K.M.;
RT   "ATM acts downstream of ATR in the DNA damage response signaling of
RT   bystander cells.";
RL   Cancer Res. 68:7059-7065(2008).
//